As interest in bacteriophage therapy grows as a response to antimicrobial resistance, EMA convenes regulators, scientists, clinicians, developers and patient representatives for a full day — — to discuss how an adapted EU regulatory framework for phage therapy could be designed.
Dates and format
- Date: 30 October 2026, 09:00–18:00 CET
- Format: online, broadcast from EMA, Amsterdam
- Organizer: European Medicines Agency (EMA)
- Audience: regulators, policymakers, scientists, clinicians, developers and patient representatives
What it covers
Bacteriophages — viruses that infect and kill specific bacteria — are drawing renewed regulatory attention as a potential tool against antimicrobial-resistant infections, but existing EU medicines rules were not written with their highly personalised, often small-batch production in mind. This workshop discusses the current regulatory landscape and the scientific and clinical evidence for phage therapy, working toward recommendations that could shape future EU delegated acts under the new EU pharmaceutical legislation. EMA runs it alongside a broader autumn calendar of stakeholder sessions, including its SME Info Day the following week.
Who should attend
Regulatory affairs and scientific leads at organisations developing phage or other novel antimicrobial therapies, plus clinicians and policy staff tracking how the EU's new pharmaceutical legislation will treat personalised biological products. For the broader EU clinical-trial agenda, EMA's ACT EU workshop on multiplicity in confirmatory trials runs a few weeks later, and the full events directory lists everything we have verified.
Frequently asked questions
When is the EMA workshop on bacteriophage therapy?
Friday, 30 October 2026, 09:00–18:00 Amsterdam time (CET) — a full-day session.
Is the workshop online or in person?
EMA lists it as an online event, with a physical location at the EMA's Amsterdam office. It isn't stated whether outside participants can attend in person or whether that location is solely where the broadcast originates — confirm access directly with EMA before making plans.
Who is this workshop for?
EMA describes the intended participants as regulators, policymakers, scientists, clinicians, developers and patient representatives working on or affected by bacteriophage (phage) therapy.
What is the workshop meant to achieve?
Discussion of the current regulatory landscape and the scientific and clinical evidence for phage therapy, working toward recommendations to help shape future EU delegated acts on phage therapy under the new EU pharmaceutical legislation.
Sources & further reading
- EMA. European Medicines Agency workshop on bacteriophage therapy, 30/10/2026. ema.europa.eu
- EU Agenda. European Medicines Agency workshop on bacteriophage therapy. euagenda.eu
Event details are published by the organizer and can change. Confirm dates, format, fees and access with EMA before making plans. Verified via WebSearch corroboration against an independent mirror (direct organizer-page fetch was blocked this session) — last checked 10 October 2026.
